Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Q2 2025 earnings

Reported July 31, 2025 · Before market open

Revenue$773.7MBeat by $110.8MDiluted EPS$0.32Beat by $0.86
Revenue estimate$662.9M
EPS estimate-$0.54

Next report

Jul 30, 2026 (In 2 weeks)
Revenue estimate$1.3B
EPS estimate$1.61

Financials

Q2 2025

Income statement

See full
Revenue$773.7M+17.3%
Gross profit$631.7M+6.6%
Operating income-$16.2M-133%
Net income-$66.3M-292%
EPS (diluted)-$0.51-292%

Balance sheet

See full
Cash & equivalents$1.1B+14.9%
Total debt$270.5M-3.7%
Total equity$250.6M+8,271%
Total assets$4.6B+13.9%

Cash flow

See full
Operating cash flow$155.7M+25.4%
CapEx$14.3M+78.3%
Free cash flow$141.4M+21.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$42.38B+37.9%
Enterprise value$41.53B+38.2%
P/S17.2×+4.1×

Profitability

See full
Gross margin83.9%-4.5pp
Operating margin-7.3%-11.7pp
Net margin-11.4%-18.2pp
FCF margin-2.1%—

Returns & leverage

See full
Debt / equity1.1×—
Current ratio2.8×-0.2×

Segments

By product

See full
AMVUTTRA$492.0M—
GIVLAARI$80.8M—
ONPATTRO$52.5M—
OXLUMO$46.9M—

Versus estimates

Revenue

Q1 2026$1.2BBeat by $51.7MQ4 2025$1.1BMiss by $52.1MQ3 2025$1.2BBeat by $289.6M
Q2 2025$773.7MBeat by $110.8M
Q1 2025$594.2MBeat by $9.0MQ4 2024$593.2MBeat by $10.6M

Diluted EPS

Q1 2026$1.51Beat by $0.64Q4 2025$0.82Miss by $0.34Q3 2025$2.90Beat by $2.34
Q2 2025$0.32Beat by $0.86
Q1 2025-$0.01Beat by $0.88Q4 2024$0.06Beat by $0.68

Ask the moment Alnylam Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Alnylam Pharmaceuticals report Q2 2025 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q2 2025 earnings on July 31, 2025 before market open.
What were Alnylam Pharmaceuticals's Q2 2025 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $773.7M and diluted EPS of $0.32 for Q2 2025.
Did Alnylam Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $662.9M by $110.8M. EPS beat the consensus estimate of $-0.54 by $0.86.
How did Alnylam Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.3% from $659.8M a year earlier and diluted EPS declined 42.9% from $0.56.
Where can I find Alnylam Pharmaceuticals's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001178670-25-000090) directly on SEC EDGAR. The filing index links above go to sec.gov.